Literature DB >> 18499277

Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts.

Lindsey L Snyder1, Jonathan M Esser, Catherine J Pachuk, Laura F Steel.   

Abstract

RNA interference (RNAi) is a process that can target intracellular RNAs for degradation in a highly sequence-specific manner, making it a powerful tool that is being pursued in both research and therapeutic applications. Hepatitis B virus (HBV) is a serious public health problem in need of better treatment options, and aspects of its life cycle make it an excellent target for RNAi-based therapeutics. We have designed a vector that expresses interfering RNAs that target HBV transcripts, including both viral RNA replicative intermediates and mRNAs encoding viral proteins. Our vector design incorporates many features of endogenous microRNA (miRNA) gene organization that are proving useful for the development of reagents for RNAi. In particular, our vector contains an RNA pol II driven gene cassette that leads to tissue-specific expression and efficient processing of multiple interfering RNAs from a single transcript, without the co-expression of any protein product. This vector shows potent silencing of HBV targets in cell culture models of HBV infection. The vector design will be applicable to silencing of additional cellular or disease-related genes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499277      PMCID: PMC2573035          DOI: 10.1016/j.antiviral.2008.04.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  45 in total

Review 1.  The silent revolution: RNA interference as basic biology, research tool, and therapeutic.

Authors:  Derek M Dykxhoorn; Judy Lieberman
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

2.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 3.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

4.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

5.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.

Authors:  David V Morrissey; Karin Blanchard; Lucinda Shaw; Kristi Jensen; Jennifer A Lockridge; Brent Dickinson; James A McSwiggen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Barry A Polisky; Shawn Zinnen
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs.

Authors:  Steffen Schubert; Hans-Peter Grunert; Heinz Zeichhardt; Denise Werk; Volker A Erdmann; Jens Kurreck
Journal:  J Mol Biol       Date:  2004-12-23       Impact factor: 5.469

7.  Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.

Authors:  Susan L Uprichard; Bryan Boyd; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-07       Impact factor: 11.205

8.  Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors.

Authors:  Michael D Moore; Michael J McGarvey; Rebecca A Russell; Bryan R Cullen; Myra O McClure
Journal:  J Gene Med       Date:  2005-07       Impact factor: 4.565

9.  Clustering and conservation patterns of human microRNAs.

Authors:  Yael Altuvia; Pablo Landgraf; Gila Lithwick; Naama Elefant; Sébastien Pfeffer; Alexei Aravin; Michael J Brownstein; Thomas Tuschl; Hanah Margalit
Journal:  Nucleic Acids Res       Date:  2005-05-12       Impact factor: 16.971

10.  An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi.

Authors:  Hongxia Zhou; Xu Gang Xia; Zuoshang Xu
Journal:  Nucleic Acids Res       Date:  2005-04-01       Impact factor: 16.971

View more
  14 in total

1.  Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.

Authors:  Mario Amendola; Laura Passerini; Ferdinando Pucci; Bernhard Gentner; Rosa Bacchetta; Luigi Naldini
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

2.  Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

Authors:  Touraj Farazmandfar; Mohammad Reza Haghshenas; Majid Shahbazi
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

Review 3.  Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases.

Authors:  Jason Lamontagne; Laura F Steel; Michael J Bouchard
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

4.  Comparative studies of various artificial microRNA expression vectors for RNAi in mammalian cells.

Authors:  Tao Hu; Ping Chen; Qiong Fu; Ye Liu; Musarat Ishaq; Junwei Li; Li Ma; Deyin Guo
Journal:  Mol Biotechnol       Date:  2010-09       Impact factor: 2.695

5.  A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition.

Authors:  Abtin Behmardi; Touraj Farazmandfar
Journal:  Drug Deliv Transl Res       Date:  2022-01-31       Impact factor: 5.671

6.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

7.  A re-examination of global suppression of RNA interference by HIV-1.

Authors:  Viraj R Sanghvi; Laura F Steel
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

8.  An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation.

Authors:  Xiaoyan Liu; Hong Fang; Hongchao Chen; Xiaoling Jiang; Deren Fang; Yan Wang; Dingxian Zhu
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

9.  RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs.

Authors:  Lindsey L Snyder; Iqbal Ahmed; Laura F Steel
Journal:  Nucleic Acids Res       Date:  2009-08-13       Impact factor: 16.971

Review 10.  Silencing viral microRNA as a novel antiviral therapy?

Authors:  Ugo Moens
Journal:  J Biomed Biotechnol       Date:  2009-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.